1. Home
  2. PBYI

PBYI

Puma Biotechnology Inc

Logo Puma Biotechnology Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Founded: 2010 Country:
United States
United States
Employees: N/A City: LOS ANGELES
Market Cap: 266.3M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 623.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.45 EPS Growth: N/A
52 Week Low/High: $2.13 - $7.73 Next Earning Date: 05-02-2024
Revenue: $235,637,000 Revenue Growth: 3.34%
Revenue Growth (this year): -5.1% Revenue Growth (next year): -1.01%

Share on Social Networks: